National Institute for Viral Disease Control and Prevention

The efficacy, immunogenicity and safety of the LZ901 vaccine for herpes zoster virus in adults 40 years of age or older: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

In previously completed Phase 1 and 2 clinical trials, a recombinant gE-Fc fusion protein subunit vaccine adjuvanted with aluminum hydroxide (called LZ901) demonstrated favorable safety profiles and elicited robust immune responses. This randomized, placebo-controlled, double-bli...